tapebrief
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

GEHC · Q3 2025 Earnings

GE HealthCare

Reported October 29, 2025

30-second summary

30-second take. GE HealthCare delivered Q3 revenue of $5.14B (+6% YoY reported, +4% organic) and non-GAAP EPS of $1.07, both ahead of the 2-3% organic and "high-single-digit EPS decline" guidance management set last quarter. The FY2025 adjusted EPS low end was raised $0.08 to $4.51 (top held at $4.63), FCF and EBIT margin guides reaffirmed, and management explicitly signaled 2026 organic growth above the 2025 ~3% pace with tariffs flipping from headwind to lower-net-impact in 2026. The wrinkle: Q4 organic guided to 3-4% implies the Q3 4% may not extend, and Florcado will miss its $30M 2025 target by management's own choice.

Headline numbers

EPS

Q3 FY2025

$1.07

Revenue

Q3 FY2025

$5.14B

+6.0% YoY

Gross margin

Q3 FY2025

38.7%

Free cash flow

Q3 FY2025

$0.48B

Operating margin

Q3 FY2025

12.7%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$5.14B+6.0%$5.01B+2.7%
EPS$1.07$1.06+0.9%
Gross margin38.7%39.6%-90bps
Operating margin12.7%13.1%-40bps
Free cash flow$0.48B$0.01B+6800.0%

Guidance

Q3 beat organic revenue and EPS expectations; full-year FY2025 guidance narrowed upward with reaffirmed organic growth and profitability targets.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Organic Revenue GrowthQ3 FY20252% to 3%4%+1 pt above high end of guideBeat
Adjusted EPSQ3 FY2025decline high single digits YoY1.07Exceeded qualitative decline guidance; Q3 EPS grew vs guidance expectation despite tariff headwindsBeat

New guidance

MetricPeriodGuideYoY
Organic Revenue GrowthQ4 FY20253% to 4%

Reaffirmed unchanged this quarter: Adjusted EPS ($4.51 to $4.63), Organic Revenue Growth (approximately 3%), Adjusted EBIT Margin (15.2% to 15.4%), Adjusted Effective Tax Rate (20% to 21%), Free Cash Flow (at least $1.4 billion)

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
Imaging$2.349B+4.0%
Advanced Visualization Solutions$1.301B+6.0%
Patient Care Solutions$0.731B-7.0%
Pharmaceutical Diagnostics$0.749B+10.0%

Other KPIs

Q3 FY2025
SegmentQ3 FY2025
Organic Revenue Growth4%
Organic Orders Growth6%
Book-to-Bill Ratio1.06x
Adjusted EBIT Margin14.8%
Net Income Margin8.7%
Operating Cash Flow$593 million
Tariff Impact on Adjusted EBIT$265 million FY headwind
Tariff Impact on Adjusted EPS$0.45 FY headwind

Management tone

Q1 anchor (tariff shock + raised FY) → Q2 anchor (tariff mitigation, H2 product cycle teed up) → Q3 anchor (2026 acceleration framing, tariff net impact lower in 2026).

Tariffs moved from acute shock to a lower-impact 2026 setup in three quarters. In April tariffs were modeled at an 85-cent FY EPS hit; in July management cut that to 45 cents and called the mitigation actions "no regrets." This quarter, Arduini stated GEHC is "on track with our goal of delivering a lower net tariff impact in 2026 versus 2025" based on currently enacted tariffs. That is a directional commitment six months after the same item was the dominant negative variable in the model. It signals management now treats the supply-chain restructuring as structurally finished, not in-progress.

The 2026 growth posture firmed from "deferred" to explicit acceleration. Last quarter management refused to commit to a 2026 EPS growth figure on the Vijay Kumar tariff exchange. This quarter Saccaro said "it's safe to say this year our expectation is to grow approximately 3%... as we look at 26, our expectation would be to grow faster than 3%," and Arduini reinforced with "we're entering a new wave of innovation across the enterprise, and these are some of our boldest ideas yet." Paired with a 1.06x book-to-bill and 6% organic orders growth (also 6% on a trailing four-quarter basis), this is the clearest forward signal management has issued on the H2/2026 product cycle they have been positioning for the better part of a year.

Florcado was reframed mid-flight from "on track to $30M" to a deliberate miss. Last quarter Arduini confirmed the $30M FY2025 Flyrcado contribution was on track, with onboarding cycle time the bottleneck. This quarter: "in 2025, we're going to be short of the 30 million" — recharacterized as "a deliberate decision to prioritize the customer experience rather than short-term revenue." This is either real discipline on a multi-year opportunity or the polite version of "we couldn't hit it." The 2026+ "half-billion-dollar by 2028" framing is now the load-bearing claim; investors won't have a clean datapoint on whether the slow-to-go-fast call paid off until late 2026.

China stopped being the swing variable. In Q2 the FY guide was framed as not counting on China. This quarter Arduini stated mid-single-digit medium-term goals are "intact" even if China remains roughly flat and stable — moving China from binary upside to optional upside. This is the right thing to say if the innovation pipeline is genuinely carrying the model.

PCS narrative pivoted with explicit one-time cause and sequential recovery in hand. With Q3 PCS at -7% organic — ~5 points of which was the now-resolved product hold — management was explicit that Q4 will show a meaningful sequential step-up in both revenue and EBIT margin as shipments resume. The forward language ("significant improvements," "meaningful improvement") is now backed by an identified mechanical recovery, not just leadership change.

Recurring themes management leaned on this quarter:

Innovation portfolio maturation driving margin accretion (AVS model replicating across imaging, PCS)AI-enabled product differentiation capturing price and share gainsSupply chain resilience and tariff mitigation offsetting macro headwindsFlorcado strategic ramp prioritizes customer workflow conversion over 2025 revenue targetsMulti-year enterprise deals and recurring revenue expanding predictabilityPCS turnaround narrative with new leadership and product launches

Risks management surfaced:

China market recovery remains uncertain despite improving tender activityPCS product hold recovery timing bleeds into 2026Florcado manufacturing yield consistency dependent on CMO executionTariff policy changes could alter 2026 mitigation assumptionsRegulatory timing for photon counting and other major launches

Answers to last quarter's watch list

Q3 organic growth above the 2-3% guide. Beat — 4% organic, a full point above the high end on a quarter management had pre-positioned conservatively. Validates that the FY ~3% raise carries cushion rather than stretch.
Resolved positively
Pharmaceutical Diagnostics organic trajectory as CMOs come online and NMP anniversaries. Reported +20% (+10% organic) held up well as the acquisition base normalizes, but Florcado's $30M 2025 target was abandoned by management's own choice — the segment is delivering on existing tracers, not the new ramp. Status: Resolved positively (segment), Resolved negatively (Florcado specifically)
Imaging EBIT margin recovery from 8.5%. Top line accelerated to +4% organic from +2%, suggesting the H2 product launches are landing; segment EBIT margin declined 260 bps YoY largely on tariffs, with management noting sequential improvement in both revenue and margin.
Continue monitoring
PCS margin stabilization. Mixed — organic revenue fell 7% YoY, but ~5 points was a now-resolved product hold, and shipments have resumed with a meaningful sequential Q4 step-up expected in both revenue and EBIT margin. Underlying structural read is better than the headline; recovery is already underway. Status: Resolved (mechanical), Continue monitoring (underlying)
2026 tariff exposure disclosure. Better than the "less than 45 cents" prior framing — Arduini stated GEHC is on track to deliver a lower net tariff impact in 2026 vs. 2025 at currently enacted rates. The full 2026 EPS roll-forward isn't disclosed yet, but the directional improvement means the durability question on the 2025 EPS raise looks less worrying.
Resolved positively
Flyrcado onboarding time from 90 days toward 30-day goal. Not disclosed in the press release; the more salient development is the strategic decision to miss the $30M 2025 target entirely, which subsumes the original cycle-time watch.
Not resolved

What to watch into next quarter

Whether Q4 organic lands at the high end of the 3-4% guide or above. A 4%+ print would extend Q3's acceleration; anything below 3% would validate the hidden-cut read that growth is decelerating into year-end.

2026 organic growth guide at Q4 print. Management has signaled above ~3% — the first explicit range is the test of how much above. A 4%+ midpoint would justify the inflection narrative; ~3.5% would suggest the "new wave of innovation" framing is running ahead of the model.

2026 net tariff EPS impact quantified, not just directionally lower. Even a +20-cent improvement would meaningfully change the 2026 EPS bridge versus the 2025 $4.51-$4.63 base.

PCS revenue and margin inflection in Q4. Management has committed to a meaningful sequential step-up as the product hold unwinds; anything less than a clear move off the Q3 trough would force a harder question on the underlying segment, separate from the one-time hold.

Florcado FY2025 actual contribution versus the abandoned $30M target. The reset is now in management's voice; the actual figure frames the credibility of the half-billion-dollar by 2028 ambition.

Imaging segment margin recovery — the +4% organic acceleration was paired with a 260 bps YoY EBIT margin decline (largely tariffs); investors need to see the photon counting / PET launches converting to margin, not just revenue, as RSNA unveils land.

Sources

  1. GE HealthCare Q3 2025 earnings press release, filed with SEC: https://www.sec.gov/Archives/edgar/data/1932393/000193239325000052/release3q25earnings.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.